Shannon Kearney, DO
Allergy · Bethlehem, PANPI 1306843149
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 60.1% of it on its own, with 49 other manufacturers making up the rest. 2025 is the largest year on record at $14,811, more than ten times the $1,199 reported in 2019. Among allergy clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 887 payments — averaging $53.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$29K
- Sanofi$3K
- CSL Behring$3K
- GSK$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $7K from 44 others
What the payments were for
- Speaking & faculty fees$21,37545%
- Travel & lodging$1,6774%
- Food & beverage$24,20151%
- Education$5541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$47,807 in reported general payments places this provider in the 90th percentile of 25 allergy providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrladeyoBerotralstat Hydrochloride | 13 | $559,712 |
| HaegardaC1 Esterase Inhibitor | 11 | $371,887 |
| Dupixent SyringeDupilumab | 61 | $273,957 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $75,485 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 59 | $38,880 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $31,049 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 74 | $14,123 |
| Spiriva RespimatTiotropium Bromide | 16 | $13,372 |
| Mometasone Furoate | 157 | $12,347 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $9,497 |
| Arnuity ElliptaFluticasone Furoate | 26 | $8,995 |
| Azelastine Hcl | 250 | $8,333 |
| Epinephrine | 30 | $6,419 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 32 | $6,209 |
| Cromolyn Sodium | 18 | $5,518 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biocryst US Sales Co., LLCOrladeyo | $953 | $559,71213 claims |
| CSL BehringHaegarda | $2,842 | $371,88711 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $2,480 | $115,529142 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $28,744 | $48,37780 claims |
| Boehringer IngelheimSpiriva Respimat | $518 | $13,37216 claims |
| Hikma Pharmaceuticals USAEpinephrine | $23 | $6,41930 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $21 | $5,51818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 25 allergy providers in Pennsylvania.
Other allergy in Bethlehem
- Michael PalumboPittsburgh$561K
- James DeangeloPittsburgh$79K
- Rehan MujahidWind Gap$16K
- Schweta ArakaliAllentown$12K
- Michelle WeissYork$7K
- David MillerPittsburgh$7K
- Andrew MurphyWest Chester$6K
- Victoria CorreaDoylestown$3K
- Thomas MakinWexford$3K
- Neil FeldmanAllentown$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.